Overview

Cost-effectiveness of Adalimumab and Surgery vs Adalimumab in HS

Status:
Recruiting
Trial end date:
2022-07-31
Target enrollment:
Participant gender:
Summary
The primary objective of this randomized controlled clinical trial in a real life setting is to evaluate the cost-utility of limumab monotherapy compared with the combination of adalimumab and a maximum of three surgeries after two years of treatment in adult patients with moderate to severe HS.
Phase:
Phase 4
Details
Lead Sponsor:
Erasmus Medical Center
Collaborators:
Sanquin
Sanquin Plasma Products BV
Treatments:
Adalimumab